LifeStance Health Group (NASDAQ:LFST) Shares Gap Down – Here’s Why

LifeStance Health Group, Inc. (NASDAQ:LFST)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $8.85, but opened at $8.01. LifeStance Health Group shares last traded at $7.8550, with a volume of 8,493,151 shares changing hands.

LifeStance Health Group News Roundup

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q1 results beat expectations — LFST reported $0.04 EPS vs. $0.01 consensus and revenue of $403.5M (up 21.2% YoY), showing solid top-line growth that supported earlier upside in the shares. Q1 Earnings / Transcript
• Positive Sentiment: Raised revenue guidance — company updated Q2 and FY2026 revenue guidance (Q2: ~$405M–$425M; FY: ~$1.6B–$1.7B), signaling continued growth expectations that support medium-term fundamentals. Q1 Results / Guidance
• Positive Sentiment: Analyst support increased — BTIG bumped its price target to $12 and issued a Buy (large upside vs. recent levels); broker consensus is skewing to Buy, reinforcing analyst optimism. BTIG Price Target Raise Brokerage Consensus
• Neutral Sentiment: Shares earlier hit a multi-year high on the earnings/guidance beat, reflecting positive momentum that preceded today’s pullback. Yahoo: 2-Year High
• Negative Sentiment: Major secondary offering launched/priced — certain stockholders are selling 35M shares at $8.15/share; LifeStance itself is not selling and receives no proceeds. Large planned sales by existing holders can increase supply and pressure the stock despite the company’s solid results. Pricing of Secondary Offering
• Negative Sentiment: Insider and existing-holder selling is notable — historical insider sales and the large block sale by major holders (35M shares) increase near-term dilution/selling risk; the company did, however, authorize a concurrent repurchase of 6M shares which may partially offset selling pressure if executed. Quiver / Offering & Repurchase

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. BTIG Research raised their price target on shares of LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a report on Friday. KeyCorp upped their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Jefferies Financial Group raised shares of LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th. Barclays upped their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, March 6th. Finally, Weiss Ratings raised shares of LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $10.00.

LifeStance Health Group Trading Down 11.2%

The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $6.80 and its 200-day moving average is $6.68. The firm has a market cap of $3.05 billion, a P/E ratio of 392.95 and a beta of 1.20.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. As a group, analysts forecast that LifeStance Health Group, Inc. will post 0.09 earnings per share for the current fiscal year.

LifeStance Health Group announced that its Board of Directors has initiated a share repurchase program on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the company to buy up to 3.6% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director Darren M. Black sold 4,314,939 shares of LifeStance Health Group stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $7.01, for a total value of $30,247,722.39. Following the completion of the sale, the director owned 29,209,776 shares in the company, valued at approximately $204,760,529.76. The trade was a 12.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Bessler sold 62,147 shares of LifeStance Health Group stock in a transaction on Friday, April 24th. The stock was sold at an average price of $7.05, for a total transaction of $438,136.35. Following the completion of the sale, the director owned 1,274,448 shares of the company’s stock, valued at approximately $8,984,858.40. This trade represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 4,389,939 shares of company stock valued at $30,775,881. Insiders own 3.20% of the company’s stock.

Institutional Trading of LifeStance Health Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after purchasing an additional 3,086,506 shares during the period. Silversmith Partners I GP LLC acquired a new position in LifeStance Health Group in the fourth quarter worth $100,842,000. Dimensional Fund Advisors LP boosted its holdings in LifeStance Health Group by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock worth $66,038,000 after purchasing an additional 1,461,215 shares during the period. Jennison Associates LLC boosted its holdings in LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after purchasing an additional 2,843,388 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in LifeStance Health Group by 27.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock worth $43,071,000 after purchasing an additional 1,324,691 shares during the period. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.